Modulating and Monitoring the Foreign Body Response to Implants
Modulating and Monitoring the Foreign Body Response to Implants
批准号:
8334392
负责人:
JULIE A STENKEN
金额:
$35.77万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-09-19 至 2015-08-31
关键词:
Adrenal Cortex HormonesAnimal ModelAnimalsAnti-Inflammatory AgentsAnti-inflammatoryAntipyrineArea Under CurveBiomedical EngineeringCalibrationCarbohydratesCellsCellular InfiltrationChemical AgentsChemicalsClinicalCollagenComplexCuesCytokine SignalingDevicesDexamethasoneDinoprostoneDoseEffectivenessEpoprostenolFDA approvedFibroblastsFibrosisFingersFluorescenceForeign BodiesForeign-Body ReactionGlucoseHealedIloprostImageImmuneImmune responseImplantIn VitroInflammationInfusion proceduresInsulinInterleukin-10LabelLongevityMajor Histocompatibility ComplexMeasurementMeasuresMediator of activation proteinMedical DeviceMembraneMethodsMicrodialysisMolecularMonitorMovementOutcomePathway interactionsPatientsPerformancePharmaceutical PreparationsPhenotypePlagueProcessProstaglandinsPublic HealthPumpRattusReadingRelative (related person)SamplingSignal TransductionSiteTestingThickTimeTissuesTranslationsVitamin B 12WorkWound Healingabstractingbaseblood glucose regulationcapsulecell typecellular imagingclinically significantcytokineglucose monitorglucose sensorhealingimplant materialimplantable deviceimplantationimplanted sensorimprovedin vivoinorganic phosphatemacrophagemonitoring deviceresearch studyresponsesensorsolutetype I and type II diabetes
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract
CLINICAL SIGNIFICANCE. All implanted materials elicit an immune response that leads to the
foreign body reaction. This foreign body reaction often causes fibrosis around the implant. For
implants such as glucose sensors, the fibrosis is one of the primary causes for limiting current
FDA-approved implanted glucose sensors to 5 to 7 days for clinical decisions (e.g., to inject
insulin or to consume carbohydrate). Macrophages are believed to provide the complex
bioactive molecular cues that direct the foreign body reaction leading to fibrosis of the implant.
Our hypothesis is that directing the polarization of macrophages to a wound healing M2c
phenotype will promote healing and tissue integration without excessive fibrosis or inflammation.
Completion of this work will provide significant in vivo bioactive agent pathway information to
create and rapidly assess new and improved bioengineering approaches to reduce or eliminate
the fibrosis associated with the foreign body reaction. Additionally, these studies will provide
important quantitative molecular information with respect to cytokine pathways altered during
efficacious methods that alter macrophage phenotype.
EXPERIMENTAL APPROACH. Microdialysis sampling probes will be used as glucose sensor
mimics that can concomitantly deliver mediators aimed to alter macrophage phenotype while
sampling the bioactive cytokines produced at the implant/tissue interface in rats. This approach
will allow rapid testing of different drugs or cytokines with the aim of directing macrophages to
the wound healing M2c phenotype. The compounds that will be used in this study to direct
macrophage polarization include interleukin-10 (IL-10), an anti-inflammatory cytokine;
dexamethasone, an anti-inflammatory corticosteroid; iloprost (PGI2), a promising anti-fibrotic
agent; and PGE2, an endogenous prostaglandin known to reduce fibrosis. The microdialysis
probe will be used to collect the cytokines produced during polarization alteration to predict
successful conversion to the M2c polarization state. The microdialysis probe will also be used
to assess how device calibration and longevity is altered during the different treatments. Real-
time whole animal cellular imaging will be employed to image cellular movement to the
implanted device. The combination of these approaches will provide rapid translation of in vitro
studies to animal models with efficacy verification.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
In Vivo Brain Dialysis of Neuropeptides and Neuroimmune Signaling Proteins
-
批准号:8244124
-
项目类别:
-
资助金额:$20.2万
-
财政年份:2011
-
负责人:JULIE A STENKEN
-
依托单位:
Modulating and Monitoring the Foreign Body Response to Implants
-
批准号:8223103
-
项目类别:
-
资助金额:$28.32万
-
财政年份:2011
-
负责人:JULIE A STENKEN
-
依托单位:
In Vivo Brain Dialysis of Neuropeptides and Neuroimmune Signaling Proteins
-
批准号:8328931
-
项目类别:
-
资助金额:$17.31万
-
财政年份:2011
-
负责人:JULIE A STENKEN
-
依托单位:
Modulating and Monitoring the Foreign Body Response to Implants
-
批准号:8740165
-
项目类别:
-
资助金额:$33.28万
-
财政年份:2011
-
负责人:JULIE A STENKEN
-
依托单位:
Modulating and Monitoring the Foreign Body Response to Implants
-
批准号:8535755
-
项目类别:
-
资助金额:$32.11万
-
财政年份:2011
-
负责人:JULIE A STENKEN
-
依托单位:
Neuropeptide Affinity Enrichment Microdialysis Sampling
-
批准号:7018756
-
项目类别:
-
资助金额:$14.0万
-
财政年份:2005
-
负责人:JULIE A STENKEN
-
依托单位:
Neuropeptide Affinity Enrichment Microdialysis Sampling
-
批准号:7140631
-
项目类别:
-
资助金额:$15.68万
-
财政年份:2005
-
负责人:JULIE A STENKEN
-
依托单位:
Quantitative Biocompatibility of Implanted Materials
-
批准号:7068122
-
项目类别:
-
资助金额:$18.96万
-
财政年份:2003
-
负责人:JULIE A STENKEN
-
依托单位:
Quantitative Biocompatibility of Implanted Materials
-
批准号:6940975
-
项目类别:
-
资助金额:$5.0万
-
财政年份:2003
-
负责人:JULIE A STENKEN
-
依托单位:
Quantitative Biocompatibility of Implanted Materials
-
批准号:6774692
-
项目类别:
-
资助金额:$21.98万
-
财政年份:2003
-
负责人:JULIE A STENKEN
-
依托单位:
Quantitative Biocompatibility of Implanted Materials
-
批准号:6898251
-
项目类别:
-
资助金额:$19.45万
-
财政年份:2003
-
负责人:JULIE A STENKEN
-
依托单位:
Quantitative Biocompatibility of Implanted Materials
-
批准号:7316830
-
项目类别:
-
资助金额:$27.63万
-
财政年份:2003
-
负责人:JULIE A STENKEN
-
依托单位:
Quantitative Biocompatibility of Implanted Materials
-
批准号:6674851
-
项目类别:
-
资助金额:$22.9万
-
财政年份:2003
-
负责人:JULIE A STENKEN
-
依托单位:
Quantitative Biocompatibility of Implanted Materials
-
批准号:7619899
-
项目类别:
-
资助金额:$26.78万
-
财政年份:2003
-
负责人:JULIE A STENKEN
-
依托单位:
Quantitative Biocompatibility of Implanted Materials
-
批准号:7916727
-
项目类别:
-
资助金额:$26.48万
-
财政年份:2003
-
负责人:JULIE A STENKEN
-
依托单位:
海外基金